miravirsen

Miravirsen is an investigational antisense oligonucleotide drug developed for the treatment of hepatitis C virus (HCV) infection. It is a 15-base, locked nucleic acid-modified phosphorothioate oligonucleotide designed to selectively bind and inhibit the liver-specific microRNA 122 (miR-122), which is essential for HCV RNA stability and replication. By sequestering miR-122, miravirsen disrupts its interaction with HCV RNA, leading to degradation of viral RNA and inhibition of viral replication. Miravirsen has demonstrated antiviral activity in preclinical models and phase II clinical trials, showing dose-dependent reductions in HCV RNA levels. The drug was originally developed by Santaris Pharma using proprietary LNA technology and later further developed by Roche after acquisition[1][5][7][8].

Other names

miravirsen sodiumLNA-antimiR-122LNA-antimiR122LNA-antimiR 122miR-122 antagonistmiR122 antagonistmiR 122 antagonistSPC3649 Parent AcidSPC-3649 Parent AcidSPC 3649 Parent Acid